Global Research Trends on Tuberculosis: A Bibliometric and Visualized Study of Clinical Trials.

Q3 Medicine
Tanaffos Pub Date : 2025-03-01
Mansoureh Feizabadi, Esmaeil Vaziri, Seyed Mohammad Reza Nejatollahi, Elham Sadati, Arman Hasanzade, Masoud Shafaghi, Fariba Ghorbani
{"title":"Global Research Trends on Tuberculosis: A Bibliometric and Visualized Study of Clinical Trials.","authors":"Mansoureh Feizabadi, Esmaeil Vaziri, Seyed Mohammad Reza Nejatollahi, Elham Sadati, Arman Hasanzade, Masoud Shafaghi, Fariba Ghorbani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberculosis stands as a prominent global infectious disease, ranking among the leading causes of mortality. Its complex pathogenesis and significant resistance to existing treatments have made the eradication of this disease challenging. Over the 20th century and into the present, numerous endeavors have been undertaken to comprehensively understand various aspects of this disease and find a proper solution to this challenge. This scientometric study employs the content analysis method to provide an overview of existing clinical trials in the tuberculosis field. We conducted a comprehensive review using the World Health Organization Clinical Trials Registry database, covering studies registered between 1998 and 2021. A total of 1,590 tuberculosis-related clinical trials were registered across global clinical trial registries through the end of 2021. Significant joint initiatives were observed, notably between South Africa and India (53 studies), South Africa and Peru (47 studies), and South Africa and Uganda (40 studies). There was a predominant focus on Human Immunodeficiency Virus (HIV) diseases (14.15% of trials). Pulmonary tuberculosis with 316 (19.87%) trials and multidrug-resistant tuberculosis with 92 (5.76%) trials were the most evaluated topics. Drug-based interventions led with 942 studies (58.25), and Isoniazid was evaluated in 261 trials (16.42%).</p><p><strong>Conclusion: </strong>Scientometric analyses provide valuable insights into research trends across diverse fields, helping researchers identify knowledge gaps and guide future investigations. The steadily increasing annual registration of clinical trials, together with persistent gaps in our understanding of tuberculosis pathogenesis, prevention, and treatment, and the substantial global burden of disease, underscores the need for continued research in this field.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"24 3","pages":"213-222"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13585148/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tanaffos","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis stands as a prominent global infectious disease, ranking among the leading causes of mortality. Its complex pathogenesis and significant resistance to existing treatments have made the eradication of this disease challenging. Over the 20th century and into the present, numerous endeavors have been undertaken to comprehensively understand various aspects of this disease and find a proper solution to this challenge. This scientometric study employs the content analysis method to provide an overview of existing clinical trials in the tuberculosis field. We conducted a comprehensive review using the World Health Organization Clinical Trials Registry database, covering studies registered between 1998 and 2021. A total of 1,590 tuberculosis-related clinical trials were registered across global clinical trial registries through the end of 2021. Significant joint initiatives were observed, notably between South Africa and India (53 studies), South Africa and Peru (47 studies), and South Africa and Uganda (40 studies). There was a predominant focus on Human Immunodeficiency Virus (HIV) diseases (14.15% of trials). Pulmonary tuberculosis with 316 (19.87%) trials and multidrug-resistant tuberculosis with 92 (5.76%) trials were the most evaluated topics. Drug-based interventions led with 942 studies (58.25), and Isoniazid was evaluated in 261 trials (16.42%).

Conclusion: Scientometric analyses provide valuable insights into research trends across diverse fields, helping researchers identify knowledge gaps and guide future investigations. The steadily increasing annual registration of clinical trials, together with persistent gaps in our understanding of tuberculosis pathogenesis, prevention, and treatment, and the substantial global burden of disease, underscores the need for continued research in this field.

结核病的全球研究趋势:临床试验的文献计量和可视化研究。
结核病是一种突出的全球传染病,是导致死亡的主要原因之一。其复杂的发病机制和对现有治疗的显著抗性使得根除这种疾病具有挑战性。从20世纪到现在,人们进行了许多努力,以全面了解这种疾病的各个方面,并找到应对这一挑战的适当解决方案。本科学计量学研究采用内容分析的方法,提供结核病领域现有临床试验的概述。我们使用世界卫生组织临床试验注册数据库进行了全面的综述,涵盖了1998年至2021年间注册的研究。截至2021年底,全球临床试验注册中心共注册了1590项结核病相关临床试验。观察到重要的联合倡议,特别是在南非和印度(53项研究)、南非和秘鲁(47项研究)以及南非和乌干达(40项研究)之间。主要关注人类免疫缺陷病毒(HIV)疾病(14.15%的试验)。肺结核316例(19.87%)试验和耐多药结核病92例(5.76%)试验是评价最多的课题。以药物为基础的干预以942项研究(58.25项)为主,261项研究(16.42%)评估异烟肼。结论:科学计量学分析为不同领域的研究趋势提供了有价值的见解,帮助研究人员识别知识差距并指导未来的研究。每年临床试验注册数量的稳步增加,加上我们对结核病发病机制、预防和治疗以及全球疾病负担的认识持续存在差距,突显了在这一领域继续研究的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tanaffos
Tanaffos Medicine-Critical Care and Intensive Care Medicine
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书